<p>2025 年 11 月 27 日- 上午 03:45</p>
<p>Protagenic Therapeutics, Inc.（纳斯达克代码：PTIX）（以下简称 “公司”）今天宣布，已收到纳斯达克上市资格工作人员（以下简称 “工作人员”）的通知信，指出公司未能遵守纳斯达克上市规则 5550(b)(1)（最低股东权益）和 5250(c)(1)（定期报告的及时提交）。</p>
<p>工作人员根据公司截至 2025 年 6 月 30 日的 10-QT 过渡报告中报告的股东权益，确定公司不再满足上市规则 5550(b)(1) 下的最低 250 万美元股东权益要求。工作人员还通知公司，延迟提交截至 2025 年 9 月 30 日的 10-Q 表格构成了根据上市规则 5250(c)(1) 的另一个不合规依据。公司正在完成最终化 10-Q 表格所需的剩余步骤，并预计将很快提交。</p>
<p>根据纳斯达克上市规则 5815，由于公司最近恢复了合规性并仍处于强制性小组监控期，工作人员已决定将公司的证券摘牌。</p>
<p>公司将及时请求在纳斯达克听证小组（以下简称 “听证小组”）面前进行听证。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>●</td>
<td>提交听证请求将自动暂停任何停牌 15 个日历日。</td>
</tr>
<tr>
<td></td>
<td>●</td>
<td>公司还将请求在听证小组决定期间暂停停牌。</td>
</tr>
<tr>
<td></td>
<td>●</td>
<td>在自动暂停期间——如果获得批准，延长暂停期间——公司的股票将继续在纳斯达克资本市场交易。</td>
</tr>
</tbody>
</table>
<p>不能保证听证小组会授予延长暂停或额外的合规时间。公司打算在听证会上提出其解决这两个缺陷的计划。</p>
<p><strong>关于 Protagenic Therapeutics, Inc.</strong></p>
<p>Protagenic Therapeutics, Inc.（纳斯达克代码：PTIX）是一家临床阶段的生物制药公司，专注于开发用于神经和神经精神疾病的治疗药物。更多信息请访问 www.protagenic.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中的声明包含美国联邦证券法意义上的 “前瞻性声明”。前瞻性声明可以通过诸如 “项目”、“可能”、“将”、“可以”、“会”、“应该”、“相信”、“期望”、“预期”、“估计”、“打算”、“计划”、“潜在”、“承诺” 或类似的未来时期的参考词来识别。本报告中的前瞻性声明的示例包括但不限于关于公司预计提交其 10-Q 季度报告、公司计划在听证小组面前上诉以及在上诉期间公司证券的持续上市的声明。前瞻性声明并非历史事实或未来表现的保证。相反，它们基于公司当前对其业务未来、未来计划、战略、预测、预期事件和趋势、经济及其他未来条件的信念、期望和假设。由于前瞻性声明涉及未来，因此它们受到固有风险和不确定性的影响，实际结果可能与前瞻性声明中所述的结果有重大差异。可能导致实际结果不同的重要因素包括但不限于，不能保证公司会提交 10-Q 表格，不能保证公司会满足纳斯达克合规标准，不能保证纳斯达克会根据需要授予公司任何免于摘牌的救济，或公司是否能够同意或最终满足任何此类救济的适用纳斯达克要求，以及在公司向 SEC 提交的文件中描述的其他重要因素。在本报告中公司所作的任何前瞻性声明仅基于当前可用的信息，并仅在声明作出之日有效。除非适用法律要求，否则公司明确不承担公开更新任何前瞻性声明的义务，无论是书面还是口头，无论是由于新信息、未来发展还是其他原因。</p>
<p><strong>公司联系方式：</strong></p>
<p>Alexander K. Arrow, MD, CFA</p>
<p>首席财务官</p>
<p>Protagenic Therapeutics, Inc.</p>
<p>149 Fifth Ave, Suite 500, New York, NY 10010</p>
<p>电话：213-260-4342</p>
<p>电子邮件：alex.arrow@protagenic.com</p>
<p><strong>来源：</strong> Protagenic Therapeutics, Inc.</p>
<p>查看原始新闻稿请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExMjU4Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExMjU4Ng"/></p>

PTIX

<p>Protagenic Therapeutics 收到了纳斯达克的非合规通知，原因是未能满足股东权益和及时提交要求。该公司计划对退市决定提出上诉，并预计将很快提交延迟的 10-Q 表格。在上诉过程中，该公司的股票将继续在纳斯达克交易。无法保证会获得延长停留或合规时间</p>

<p>11/27/2025 - 03:45 AM</p>
<div class="lb-trans"><p>2025 年 11 月 27 日- 上午 03:45</p>
</div><p>Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the &#34;Company&#34;) today announced that it has received a notification letter from the Nasdaq Listing Qualifications Staff (the &#34;Staff&#34;) indicating that the Company is not in compliance with Nasdaq Listing Rules 5550(b)(1) (minimum stockholders' equity) and 5250(c)(1) (timely filing of periodic reports).</p>
<div class="lb-trans"><p>Protagenic Therapeutics, Inc.（纳斯达克代码：PTIX）（以下简称 “公司”）今天宣布，已收到纳斯达克上市资格工作人员（以下简称 “工作人员”）的通知信，指出公司未能遵守纳斯达克上市规则 5550(b)(1)（最低股东权益）和 5250(c)(1)（定期报告的及时提交）。</p>
</div><p>The Staff determined that, based on the stockholders' equity reported in the Company's Transition Report on Form 10-QT for the period ended June 30, 2025, the Company no longer satisfies the minimum $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1). The Staff also notified the Company that the delayed filing of its Form 10-Q for the quarter ended September 30, 2025 constitutes a separate basis for non-compliance under Listing Rule 5250(c)(1). The Company is completing the remaining steps needed to finalize the Form 10-Q and expects to file it imminently.</p>
<div class="lb-trans"><p>工作人员根据公司截至 2025 年 6 月 30 日的 10-QT 过渡报告中报告的股东权益，确定公司不再满足上市规则 5550(b)(1) 下的最低 250 万美元股东权益要求。工作人员还通知公司，延迟提交截至 2025 年 9 月 30 日的 10-Q 表格构成了根据上市规则 5250(c)(1) 的另一个不合规依据。公司正在完成最终化 10-Q 表格所需的剩余步骤，并预计将很快提交。</p>
</div><p>Under Nasdaq Listing Rule 5815, because the Company recently regained compliance and remains subject to a mandatory panel monitoring period, the Staff has issued a determination to delist the Company's securities.</p>
<div class="lb-trans"><p>根据纳斯达克上市规则 5815，由于公司最近恢复了合规性并仍处于强制性小组监控期，工作人员已决定将公司的证券摘牌。</p>
</div><p>The Company will timely request a hearing before a Nasdaq Hearings Panel (the &#34;Panel&#34;).</p>
<div class="lb-trans"><p>公司将及时请求在纳斯达克听证小组（以下简称 “听证小组”）面前进行听证。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>●</td>
<td>Filing the hearing request automatically stays any suspension for 15 calendar days.</td>
</tr>
<tr>
<td></td>
<td>●</td>
<td>The Company will also request a stay of suspension pending the Panel's decision.</td>
</tr>
<tr>
<td></td>
<td>●</td>
<td>During the automatic stay - and, if granted, the extended stay - the Company's stock will continue to trade on The Nasdaq Capital Market.</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>●</td>
<td>提交听证请求将自动暂停任何停牌 15 个日历日。</td>
</tr>
<tr>
<td></td>
<td>●</td>
<td>公司还将请求在听证小组决定期间暂停停牌。</td>
</tr>
<tr>
<td></td>
<td>●</td>
<td>在自动暂停期间——如果获得批准，延长暂停期间——公司的股票将继续在纳斯达克资本市场交易。</td>
</tr>
</tbody>
</table>
</div><p>There can be no assurance that the Panel will grant an extended stay or additional time for compliance. The Company intends to present its plan to address both deficiencies at the hearing.</p>
<div class="lb-trans"><p>不能保证听证小组会授予延长暂停或额外的合规时间。公司打算在听证会上提出其解决这两个缺陷的计划。</p>
</div><p><strong>About Protagenic Therapeutics, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Protagenic Therapeutics, Inc.</strong></p>
</div><p>Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is a clinical-stage biopharmaceutical company developing therapeutics for neurological and neuropsychiatric conditions. More information is available at www.protagenic.com.</p>
<div class="lb-trans"><p>Protagenic Therapeutics, Inc.（纳斯达克代码：PTIX）是一家临床阶段的生物制药公司，专注于开发用于神经和神经精神疾病的治疗药物。更多信息请访问 www.protagenic.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Statements in this press release contain &#34;forward-looking statements&#34; within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as &#34;projects,&#34; &#34;may,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;believes,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;estimates,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;potential,&#34; &#34;promise&#34; or similar references to future periods. Examples of forward-looking statements in this current report include, without limitation, statements regarding the Company's expected filing of its Quarterly Report on Form 10-Q, the Company's planned appeal before the Panel, and the continued listing of the Company's securities pending the appeal. Forward-looking statements are statements that are not historical facts nor assurances of future performance. Instead, they are based on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties, and actual results may differ materially from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, without limitation, that there can be no assurance that the Company will file the Form 10-Q, that there can be no assurance that the Company will otherwise meet Nasdaq compliance standards, that there can be no assurance that Nasdaq will grant the Company any relief from delisting as necessary or whether the Company can agree to or ultimately meet applicable Nasdaq requirements for any such relief, and the other important factors described under the caption &#34;Risk Factors&#34; in the Company's filings with the SEC. Any forward-looking statement made by the Company in this current report is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, the Company expressly disclaims any obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>
<div class="lb-trans"><p>本新闻稿中的声明包含美国联邦证券法意义上的 “前瞻性声明”。前瞻性声明可以通过诸如 “项目”、“可能”、“将”、“可以”、“会”、“应该”、“相信”、“期望”、“预期”、“估计”、“打算”、“计划”、“潜在”、“承诺” 或类似的未来时期的参考词来识别。本报告中的前瞻性声明的示例包括但不限于关于公司预计提交其 10-Q 季度报告、公司计划在听证小组面前上诉以及在上诉期间公司证券的持续上市的声明。前瞻性声明并非历史事实或未来表现的保证。相反，它们基于公司当前对其业务未来、未来计划、战略、预测、预期事件和趋势、经济及其他未来条件的信念、期望和假设。由于前瞻性声明涉及未来，因此它们受到固有风险和不确定性的影响，实际结果可能与前瞻性声明中所述的结果有重大差异。可能导致实际结果不同的重要因素包括但不限于，不能保证公司会提交 10-Q 表格，不能保证公司会满足纳斯达克合规标准，不能保证纳斯达克会根据需要授予公司任何免于摘牌的救济，或公司是否能够同意或最终满足任何此类救济的适用纳斯达克要求，以及在公司向 SEC 提交的文件中描述的其他重要因素。在本报告中公司所作的任何前瞻性声明仅基于当前可用的信息，并仅在声明作出之日有效。除非适用法律要求，否则公司明确不承担公开更新任何前瞻性声明的义务，无论是书面还是口头，无论是由于新信息、未来发展还是其他原因。</p>
</div><p><strong>Company Contact:</strong></p>
<div class="lb-trans"><p><strong>公司联系方式：</strong></p>
</div><p>Alexander K. Arrow, MD, CFA</p>
<div class="lb-trans"><p>Alexander K. Arrow, MD, CFA</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官</p>
</div><p>Protagenic Therapeutics, Inc.</p>
<div class="lb-trans"><p>Protagenic Therapeutics, Inc.</p>
</div><p>149 Fifth Ave, Suite 500, New York, NY 10010</p>
<div class="lb-trans"><p>149 Fifth Ave, Suite 500, New York, NY 10010</p>
</div><p>Tel: 213-260-4342</p>
<div class="lb-trans"><p>电话：213-260-4342</p>
</div><p>Email: alex.arrow@protagenic.com</p>
<div class="lb-trans"><p>电子邮件：alex.arrow@protagenic.com</p>
</div><p><strong>SOURCE:</strong> Protagenic Therapeutics, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Protagenic Therapeutics, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExMjU4Ng" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1112586"/></p>

Protagenic Therapeutics 宣布收到纳斯达克不合规通知 | PTGX 股票新闻